BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kennedy BE, Sadek M, Gujar SA. Targeted Metabolic Reprogramming to Improve the Efficacy of Oncolytic Virus Therapy. Mol Ther 2020;28:1417-21. [PMID: 32243836 DOI: 10.1016/j.ymthe.2020.03.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Kumar V, Giacomantonio MA, Gujar S. Role of Myeloid Cells in Oncolytic Reovirus-Based Cancer Therapy. Viruses 2021;13:654. [PMID: 33920168 DOI: 10.3390/v13040654] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Al-Ziaydi AG, Al-Shammari AM, Hamzah MI, Kadhim HS, Jabir MS. Hexokinase inhibition using D-Mannoheptulose enhances oncolytic newcastle disease virus-mediated killing of breast cancer cells. Cancer Cell Int 2020;20:420. [PMID: 32874134 DOI: 10.1186/s12935-020-01514-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
3 Wang L, Chard Dunmall LS, Cheng Z, Wang Y. Remodeling the tumor microenvironment by oncolytic viruses: beyond oncolysis of tumor cells for cancer treatment. J Immunother Cancer 2022;10:e004167. [PMID: 35640930 DOI: 10.1136/jitc-2021-004167] [Reference Citation Analysis]
4 Jin KT, Du WL, Liu YY, Lan HR, Si JX, Mou XZ. Oncolytic Virotherapy in Solid Tumors: The Challenges and Achievements. Cancers (Basel) 2021;13:588. [PMID: 33546172 DOI: 10.3390/cancers13040588] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Muscolini M, Tassone E, Hiscott J. Oncolytic Immunotherapy: Can't Start a Fire Without a Spark. Cytokine Growth Factor Rev 2020;56:94-101. [PMID: 32826166 DOI: 10.1016/j.cytogfr.2020.07.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Li Z, Jiang Z, Zhang Y, Huang X, Liu Q. Efficacy and Safety of Oncolytic Viruses in Randomized Controlled Trials: A Systematic Review and Meta-Analysis. Cancers (Basel) 2020;12:E1416. [PMID: 32486227 DOI: 10.3390/cancers12061416] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
7 Müller L, Berkeley R, Barr T, Ilett E, Errington-Mais F. Past, Present and Future of Oncolytic Reovirus. Cancers (Basel) 2020;12:E3219. [PMID: 33142841 DOI: 10.3390/cancers12113219] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
8 Gilchrist VH, Jémus-Gonzalez E, Said A, Alain T. Kinase inhibitors with viral oncolysis: Unmasking pharmacoviral approaches for cancer therapy. Cytokine Growth Factor Rev 2020;56:83-93. [PMID: 32690442 DOI: 10.1016/j.cytogfr.2020.07.008] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]